Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Platelet Engraftment After Allo-HSCT
NCT05727917Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hetrombopag in Thrombocytopenia (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients with platelet engraftment within 21 days after transplantation. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT05727917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727917.